Hepatic Dysfunction in Hospitalized Patients with Acute Thyrotoxicosis: A Decade of Experience

Table 1

Demographic, laboratory, echocardiographic results, and propylthiouracil use by patient.

Patient number	1	2	3	4	5	6	7	8	9	10	11
Age	81	50	55	21	26	23	42	42	56	55	50
Gender	F	F	F	M	F	M	M	M	M	F	F
TSH (mIU/L) [NR 0.3–5.0 mIU/L]	0.02	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	0.01	<0.01	0.01
Thyroxine (total; mcg/dL) [NR 5–12.5 mcg/dL]	NP	NP	11.5	NP	23.2	22.3	NP	NP	16.2	NP	NP
Thyroxine (free; ng/dL) [NR 0.8–1.8 ng/dL]	10	4.6	6	7.7	7	>12	5.4	9.4	3.2	5	3.6
Triiodothyronine (ng/dL) [NR 80–190 ng/dL]	NP	NP	462	385	NP	359	NP	NP	150	NP	NP
Free T3 (pg/mL) [NR 2.0–3.5 pg/mL]	20	8.6	NP	17.6	10.3	>20	17.6	NP	NP	12.3	43 (reverse)
TPO (IU/mL) [NR < 9.0 IU/mL]	<20	287	NP	>950	NP	4420	NP	3017	706	NP	NP
TRAB (%) [NR < 16%]	82	31	66	NP	NP	93	46	75	52	NP	53
TSI index (%) [NR ≤ 1.3%]	NP	NP	NP	7.3	NP	NP	NP	NP	NP	5	2.6
AST (U/L) [NR 8–48 U/L]	76	978	636	2850	39	30	82	34	99	52	69
ALT (U/L) [NR 7–55 U/L]	66	920	841	1895	41	27	102	53	70	41	44
ALP (U/L) [NR 45–115 U/L]	135	252	136	180	129	NP	97	NP	194	NP	162
Bilirubin (Total/Dir.; mg/dL) [NR 0.1–1.0/0.0–0.3 mg/dL]	NP	1.2/0.6	0.9/0.7	5.6/1.8	0.4/0.1	NP	0.7/0.2	NP	1.2/0.7	NP	3.6/2.5
INR [NR 0.8–1.2]	NP	1.2	1.4	2.4	1.1	1.0	1.0	1.0	1.1	1.7	1.7
Albumin (g/dL) [NR 3.5–5.0 g/dL]	NP	2.9	3.6	3.6	NP	NP	3.3	NP	3.4	3.1	3.0
Ascites	N	N	N	Y	N	N	N	N	Y	N	N
LVEF by ECHO	NP	48%	65%	20%	NP	NP	68%	45–50%	22%	29%	NP
Troponin T (ng/mL)	NP	12.38	0.07	<0.01	<0.01	<0.01	<0.01	0.11	<0.01	NP	NP
PTU prior to LFTs?	N	N	N	N	Y	N	N	N	N	Y	N
PTU after LFTs?	Y	Y	N	N	Y	Y	N	N	Y	Y	Y
LFTs worsened?	N	N	N/A	N/A	N	N	N/A	N/A	N	N	N

Y: yes, N: no, NP: not performed, N/A: not applicable.